Ropinirole
- Generic Name
- Ropinirole
- Brand Names
- Requip
- Drug Type
- Small Molecule
- Chemical Formula
- C16H24N2O
- CAS Number
- 91374-21-9
- Unique Ingredient Identifier
- 030PYR8953
- Background
Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome , . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome .
In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole .
- Indication
For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome .
- Associated Conditions
- Idiopathic Parkinson's Disease, Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
DIalysis Symptom COntrol-Restless Legs Syndrome Trial
- Conditions
- Restless Legs SyndromeEnd Stage Renal Disease
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 52
- Registration Number
- NCT03806530
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦St. Joseph's Hamilton Healthcare, Hamilton, Ontario, Canada
🇨🇦Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD
- Conditions
- Restless Legs SyndromeEnd Stage Renal Disease
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 3
- Registration Number
- NCT03708237
- Locations
- 🇨🇦
Edmonton General Continuing Care Centre, Edmonton, Canada
🇨🇦Royal Alexandra Hospital, Edmonton, Canada
🇨🇦Grey Nuns Community Hospital, Edmonton, Canada
Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Titan Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT03250117
- Locations
- 🇺🇸
Orlando, Florida, Orlando, Florida, United States
🇺🇸Kirkland, Washington, Kirkland, Washington, United States
🇺🇸Farmington Hills, Michigan, Farmington Hills, Michigan, United States
Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis
- Conditions
- Muscle CrampCirrhosis
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT03176966
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 16
- Registration Number
- NCT03038308
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
- Conditions
- Parkinson Disease
- Interventions
- First Posted Date
- 2013-08-27
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 81
- Registration Number
- NCT01929317
- Locations
- 🇯🇵
GSK Investigational Site, Shizuoka, Japan
Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fasting Conditions
- Conditions
- Pharmacokinetic Study
- Interventions
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01717235
- Locations
- 🇮🇳
Sipra Labs Limited, Hyderabad,, Andhra Pradesh,, India
Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fed Conditions
- Conditions
- Pharmacokinetic Study
- Interventions
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- Lupin Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT01714856
- Locations
- 🇮🇳
Sipra Labs Limited, Hyderabad, Andhra Pradesh, India
A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT01628926
Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 48
- Registration Number
- NCT01627834
- Locations
- 🇮🇳
GVK Biosciences Pvt. Ltd, Ameerpet, Hyderabad, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.